IP Library Granted Patent US 8,075,877
Granted Patent B2
US 8,075,877 · App. 11/713,097 · Granted Dec 13, 2011

Broad spectrum immune and antiviral gene modulation by oral interferon

Assignee: Hemispherx Biopharma
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,075,877
App. No.
11/713,097
Granted
Dec 13, 2011
Kind
B2
Abstract

An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human α-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.

Claims (17)

1. A method of inducing an antiviral/immunomodulatory response in an animal comprising orally or nasally administering to an infected animal α-interferon in an amount of at least 6.6 IU per round of the animal's body weight so that the antiviral/immunomodulatory response is induced.

2. The method of claim 1 wherein the α-interferon was purified as a mixture of at least seven species of α-interferon produced by human white blood cells.

3. The method of claim 2 wherein the α-interferon species are orally administered to a human in an amount in the range of 1000-2000 IU per day.

4. The method of claim 2 wherein the α-interferon species are orally administered to a human in an amount of at least 6.6 IU per pound of the human's body weight.

5. The method of claim 2 wherein the α-interferon species are orally administered to a human in an amount in the range of 1000-2000 IU per day.

6. The method of claim 2 wherein the α-interferon species are nasally administered to a human in an amount in the range of 1000-2000 IU per day.

7. The method of claim 2 wherein the α-interferon species are nasally administered to a human in an amount of at least 6.6 IU per pound of the human's body weight.

8. The method of claim 7 wherein the α-interferon species are nasally administered to a human in an amount in the range of 1000-2000 IU per day.

9. A method of systemically activating an innate immune response comprising orally or nasally administering to an animal α-interferon in an amount of at least 6.6 μl per pound of the animal's body weight so that the innate immune response is activated.

10. The method of claim 9 wherein the α-interferon was purified as a mixture of at least seven species of α-interferon produced by human white blood cells.

11. The method of claim 10 wherein the α-interferon species are orally administered to a human in an amount of at least 6.6 IU per pound of the human's body weight.

12. The method of claim 11 wherein the α-interferon species are orally administered to a human in an amount in the range of 1000-2000 IU per day.

13. The method of claim 10 wherein the α-interferon species are orally administered to a human in an amount in the range of 1000-2000 IU per day.

14. The method of claim 10 wherein the α-interferon species are nasally administered to a human in an amount of at least 6.6 IU per pound of the human's body weight.

15. The method of claim 14 wherein the α-interferon species are nasally administered to a human in an amount in the range of 1000-2000 IU per day.

16. The method of claim 10 wherein the α-interferon species are nasally administered to a human in an amount in the range of 1000-2000 IU per day.

17. The method of claim 1 or 9 wherein the animal is a human.

Assignments (2)
CHANGE OF NAME Recorded Oct 23, 2019
From: HEMISPHERX BIOPHARMA, INC.
To: AIM IMMUNOTECH INC.
Reel/Frame 050797/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2007
From: CARTER, WILLIAM A.; STRAYER, DAVID
To: HEMISPHERX BIOPHARMA
Reel/Frame 019416/0293 →
Continuity (2)
Provisional Application 60780079 · Mar 8, 2006
Related Publication 20090004141A1 · Jan 1, 2009